news
Cristina Adriana Popa
Top Stories in Nephrology 2025

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

Top Stories in Nephrology 2025
Background
Brian Rifkin
Dialyze Less, Recover More? AKI’s Chance to Get ...

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D
Background
Brian Rifkin
Fish Oil in Dialysis: A Big Catch or an Empty ...

Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?

Fish Oil in Dialysis: A Big Catch or an Empty Net
Background
Brian Rifkin
Attacking the Origin of IgAN: ORIGIN3 and ...

This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.

Attacking the Origin of IgAN: ORIGIN3 and Atacicept
news
swapnil hiremath
Kidney Week in Houston: Day 3

Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.

Kidney Week in Houston: Day 3

flozinate

Freely Filtered does EMPA-Kidney

Freely Filtered 054: EMPA-Kidney. EMPA-Kidney is the last of the big three to report their Kidney Endpoints SGLT2i trial (CREDENCE for Cana, DAPA-CKD for Dapa, and now EMPA-Kidney for Empa) and it answers some questions that had previously been unanswered. Join the Filtrate as they tear it apart.

Listen


Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.